rais po
risk patient volum drove materi upsid ticker ew
result rais po base assumpt
ew trade earlier within one year roughli line
highest growth peer med-tech revenu growth ep growth
came better expect respect ew tavr transcathet
aortic valv replac franchis drove upsid ew us tavr growth around
ww tavr growth ew report tavr sale
street expect
due strong growth quarter rais ep ew
magnitud increas ep estim temper
higher tax rate lower fx gain invest momentum behind ew
busi seem clear sustain sever year
earli thought
ew provid earli color tonight call formal guidanc come
ew said tavr growth next year low doubl digit seem
conserv mitral sale doubl ew also highlight potenti
headwind margin tax suggest ep could grow less revenu
ew expect downward pressur gross margin due fx currenc hedg roll
hedg contribut current rate
benefit goe away ew unlik see leverag slight
leverag sg effici off-set growth invest year tax rate
roughli benefit stock compens expect tax rate
closer model revenue growth tavr growth
ep growth model revenue growth
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
edward lifesci leader emerg
field transcathet heart valv replac
one visibl innov excit
market medic devic sector
ew heart valv busi gener
compani total revenu critic care
busi account total sale
almost attent focus
compani today due on-going pioneer
role develop transcathet heart valv
ew stand-alon tavr transcathet
aortic valv replac name one
largest fastest grow med-tech market
current believ tavr stand alongsid
coronari stent core technolog
catheter lab futur
posit ew current pipelin tmvr
see signific potenti catalyst ew
approv indic expans
po base target multipl ew ep base
assumpt ew trade roughli line highest growth peer
downsid risk price object tavr market develop risk rel
street high expect competit risk relat ew core tavr busi
risk market opportun technolog could smaller
assum upsid risk price object potenti deeper penetr
market larger market opportun model untreat high low
moder risk patient seek tavr given less invas natur
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
